Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Study on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Ninghui Yan
- Phone Number: +0518-82342973
- Email: ninghui.yan@hengrui.com
Study Contact Backup
- Name: Jing Xu
- Phone Number: +0518-82342973
- Email: jing.xu.jx23@hengrui.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-75 years old, male or female;
- BMI: 18.0-30.0 kg/m2;
- Meet the 2015 ACR/EULAR gout classification criteria;
- Fast serum uric acid ≥ 480 μmol/L on 2 different days during the screening perid;
- Willing to ues contraceptive measures during the study;
- Able and willing to provide a written informed consent.
Exclusion Criteria:
- History of acute gout attack within 4 weeks before randomization.
- Subjects who have undergone major surgery or organ transplantation within 3 months before randomization.
- Subjects with major cardiovascular disease within 6 months before randomization.
- History of chronic infection or recurrent infection within 1year before randomization.
- History of malignant tumor or current history of combined malignant tumor within 5 years before screening.
- History of secondary hyperuricemia, refractory gout, or xanthine metabolism disorder.
- Subjects with poorly controlled blood pressure or diabetes mellitus.
- History of chronic diffuse connective tissue disease and/or massively elevated urate diseases and/or untreated clinically significant thyroid disease.
- History of diseases that may affect the in vivo process, safety evaluation, or subjects' participation in the research.
- Abnormal laboratory tests that may affect subjects participating in the research.
- Combined use of prohibited drugs.
- Allergic to ingredient or component of the experimental drug.
- Participated in other clinical trials within 1 month before randomization.
- Pregnant or nursing women.
- History of drug abuse, drug use and/or excessive drinking within 1 year before screening.
- The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group A: HR091506 tablets + placebo of febuxostat tablets
|
HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
|
|
Active Comparator: Treatment group B: febuxostat tablets + placebo of HR091506 tablets
|
febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The proportion of subjects with serum uric acid level < 360 μmoL/L at Week 28
Time Frame: Week 28
|
Week 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects with serum uric acid level < 360 μmol/L at each visit.
Time Frame: at week 4,8,12,16,20and24 after administration
|
at week 4,8,12,16,20and24 after administration
|
|
Proportion of subjects with ≥1 gout flare during treatment stage
Time Frame: during treatment stage
|
during treatment stage
|
|
Proportion of subjects with serum uric acid level < 300 μmol/L at each visit
Time Frame: at week 4,8,12,16,20,24and28 after administration
|
at week 4,8,12,16,20,24and28 after administration
|
|
Change of serum uric acid level from baseline to every visit
Time Frame: at week 4,8,12,16,20,24 and28 after administration
|
at week 4,8,12,16,20,24 and28 after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Metabolism, Inborn Errors
- Crystal Arthropathies
- Purine-Pyrimidine Metabolism, Inborn Errors
- Hyperuricemia
- Gout
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Thiazoles
- Azoles
- Febuxostat
Other Study ID Numbers
Other Study ID Numbers
- HR091506-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.